Patient must be NPO for 6 hours prior to the procedure. Review recent coagulation profile and blood thinners; hold antiplatelets/anticoagulants as indicated by clinical guidelines. Obtain written informed consent. Administer prophylactic antibiotics if indicated per institutional protocol.
Monitor vital signs for 1-2 hours post-procedure. Assess for signs of abdominal pain, fever, or bleeding. Provide instructions on a clear liquid diet for the first 24 hours. The patient is discharged the same day with a follow-up appointment scheduled for stent evaluation.
Clinical Guide: Endoscopic Ultrasound-Guided Cystogastrostomy (LAMS)
1. Comprehensive Introduction & Overview
Endoscopic Ultrasound-guided (EUS) cystogastrostomy utilizing Lumen-Apposing Metal Stents (LAMS) represents a paradigm shift in the management of symptomatic pancreatic fluid collections (PFCs). Traditionally, these collections—specifically walled-off necrosis (WON) and pancreatic pseudocysts—required surgical necrosectomy or percutaneous drainage, both of which were associated with significant morbidity, prolonged hospital stays, and external fistula risks.
EUS-guided cystogastrostomy allows for the creation of a secure, fistula-like connection between the gastrointestinal lumen (stomach or duodenum) and the fluid collection. The introduction of LAMS has revolutionized this procedure by providing a large-diameter, fully covered, self-expanding stent that holds the two walls in apposition, facilitating internal drainage and, in cases of necrosis, allowing for direct endoscopic necrosectomy (DEN).
2. Technical Specifications and Mechanisms
The LAMS device is an engineered breakthrough in interventional endoscopy. Unlike traditional plastic pigtail stents, LAMS are designed with a "dumbbell" or "biconical" shape.
Key Technical Attributes:
- Design: Biconical flanges exert outward pressure on both the gastric wall and the cyst wall, creating a tight seal (lumen apposition) that prevents leakage of gastric contents into the retroperitoneum.
- Material: Typically composed of Nitinol (nickel-titanium alloy), providing high radial force and flexibility.
- Coating: Fully covered with silicone or PTFE to prevent tissue ingrowth and facilitate removal.
- Delivery System: Usually catheter-based, often integrated with an electrocautery-enhanced tip, allowing for "one-step" access without the need for traditional needle-wire exchange.
| Feature | Lumen-Apposing Metal Stent (LAMS) | Traditional Plastic Stent |
|---|---|---|
| Diameter | Large (10mm - 20mm) | Small (5Fr - 10Fr) |
| Anchoring | Biconical Flanges (Secure) | Pigtail ends (Prone to migration) |
| Drainage Capacity | High (Passes solid debris) | Low (Fluid only) |
| Risk of Leakage | Minimized by apposition | Higher risk of dislodgement |
3. Clinical Indications and Usage
The primary indication for EUS-cystogastrostomy is the management of symptomatic pancreatic fluid collections occurring as a result of acute or chronic pancreatitis.
Primary Indications:
- Pancreatic Pseudocysts: Mature, encapsulated collections with a well-defined wall, typically occurring >4 weeks after an episode of acute pancreatitis.
- Walled-Off Necrosis (WON): Collections containing both liquid and solid necrotic debris. LAMS are the gold standard here as they permit the passage of an endoscope through the stent for manual debridement.
- Symptomatic Criteria:
- Persistent abdominal pain or gastric outlet obstruction.
- Infection of the collection (fever, leukocytosis).
- Compression of adjacent structures (biliary tree, duodenum, or major vessels).
4. Pre-Operative Preparation
A rigorous pre-operative assessment is mandatory to ensure patient safety and technical success.
- Imaging: Cross-sectional imaging (CT with IV contrast or MRI/MRCP) is essential to map the anatomy, assess the distance between the gastric wall and the collection, and rule out pseudoaneurysms.
- Coagulation Profile: Patients must have an INR <1.5 and a platelet count >50,000/μL. Antiplatelet/anticoagulant therapy should be managed per ASGE guidelines.
- Antibiotic Prophylaxis: Broad-spectrum antibiotics (e.g., piperacillin-tazobactam or ceftriaxone) are administered prior to the procedure.
- Anesthesia: General anesthesia with endotracheal intubation is standard practice to protect the airway and ensure patient immobility.
5. The Procedure: Step-by-Step Intervention
The procedure is performed using a linear array echoendoscope.
- Endosonographic Evaluation: The collection is identified, and the distance between the gastric wall and the collection wall is measured. A distance of <1cm is ideal.
- Access: The electrocautery-enhanced delivery system is advanced through the stomach wall into the collection under EUS guidance.
- Deployment: The distal flange is deployed within the collection. The system is then retracted slightly to ensure the distal flange is flush against the cyst wall. The proximal flange is then deployed within the stomach lumen.
- Confirmation: Immediate flow of fluid or necrotic debris confirms successful access.
- Necrosectomy (If applicable): If the collection is WON, an endoscope is passed through the LAMS to perform irrigation and endoscopic debridement of solid necrotic tissue.
6. Post-Operative Recovery and Protocol
- Monitoring: Patients are monitored in a post-anesthesia care unit (PACU) for 2–4 hours.
- Diet: Clear liquids may be started within 4–6 hours post-procedure, advancing to a soft diet as tolerated.
- Follow-up: Repeat imaging (CT scan) is typically performed at 2–4 weeks to assess the resolution of the collection.
- Stent Removal: LAMS are usually removed 3–6 weeks after placement, once the collection has resolved and the "fistula" tract has matured.
7. Potential Complications
While highly effective, EUS-cystogastrostomy is an invasive procedure with inherent risks.
- Bleeding: Can occur due to puncture of vessels in the gastric wall or the collection wall. Often managed with endoscopic hemostasis (clips, cautery).
- Perforation: Injury to structures beyond the collection.
- Infection/Sepsis: If the collection is not adequately drained or if secondary infection occurs.
- Stent Migration: Rare, but can occur if the flanges are not properly seated.
- Late Complications: Stent obstruction by food particles or tissue ingrowth, necessitating premature removal.
8. Alternative Treatments
- Surgical Cystogastrostomy: Invasive, requiring laparotomy or laparoscopy. Reserved for cases where endoscopic access fails or if there is concomitant pathology requiring surgery (e.g., gallbladder stones).
- Percutaneous Drainage: Involves an external drain (catheter) exiting the skin. Often causes patient discomfort, skin irritation, and high risk of fistula formation.
- Conservative Management: For asymptomatic, small pseudocysts (<6cm).
9. Frequently Asked Questions (FAQ)
1. Is EUS-cystogastrostomy painful?
The procedure is performed under general anesthesia, so the patient feels no pain. Post-procedure, mild abdominal discomfort is common but usually controlled with standard analgesics.
2. How long does the LAMS stay in place?
Typically, the stent remains in place for 3 to 6 weeks to allow the collection to collapse and the tract to mature.
3. What is the success rate of this procedure?
Clinical success rates for EUS-guided drainage using LAMS exceed 90–95% in experienced centers.
4. Can I eat normally after the procedure?
Yes, once the anesthesia wears off and the patient is stable, a normal diet is typically resumed within 24 hours.
5. What are the signs of a complication?
Patients should seek immediate care for high fever, severe abdominal pain, hematemesis (vomiting blood), or melena (black/tarry stools).
6. Does the LAMS stent need to be removed?
Yes, because LAMS are designed for temporary apposition, they are typically removed to prevent long-term complications like tissue ingrowth or ulceration.
7. What if the collection does not resolve?
If the collection persists, repeat endoscopic debridement or surgical intervention may be required.
8. Are there any restrictions after the procedure?
Heavy lifting and strenuous activity should be avoided for 48–72 hours. Antiplatelet medications are usually resumed after consultation with the gastroenterologist.
9. How is the LAMS removed?
Removal is a simple endoscopic procedure using a snare or rat-tooth forceps to collapse the stent and withdraw it into the endoscope.
10. Why is EUS preferred over percutaneous drainage?
EUS-cystogastrostomy offers internal drainage, eliminating the need for external bags/tubes, improving patient quality of life, and reducing the risk of cutaneous fistulas.
10. Conclusion
EUS-guided cystogastrostomy with LAMS has redefined the management of pancreatic fluid collections. By providing a safe, minimally invasive, and highly effective internal drainage pathway, it minimizes patient morbidity and shortens recovery times. Success relies on precise patient selection, high-level endoscopic skill, and diligent post-procedural surveillance. As technology evolves, LAMS will likely continue to be the cornerstone of interventional endosonography in the management of complex pancreatic disease.
